Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Accesswire
*Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential..
*Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential..
Time and time again, the community has shown that it will rally together in support of one of its own. After 17-year-old Tatum..
A new study highlighted the risks of leukemia in children with Down syndrome. It pointed to stronger than expected associations..